Zacks Investment Research Upgrades MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) to Buy

Zacks Investment Research upgraded shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) from a hold rating to a buy rating in a research note issued to investors on Friday, Zacks.com reports. They currently have $37.00 target price on the stock.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Separately, Guggenheim assumed coverage on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a report on Wednesday, November 27th. They issued a buy rating for the company.

Shares of MOR stock opened at $32.88 on Friday. The firm has a 50-day moving average price of $34.76 and a 200 day moving average price of $29.94. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a twelve month low of $22.46 and a twelve month high of $37.96.

Further Reading: Recession

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.